Molecular approach to breast cancer treatment

Seminars in Oncology

Volumn 31, Issue SUPPL. 10, 2004, Pages 6-13

  Yarden, Yosef ^a   Baselga, José ^b   Miles, David ^c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CL 1033; DOCETAXEL; EMD 7200; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; HR 3; IMATINIB; IMCIC 11; LAPATINIB; LONAFARNIB; MDX 447; PELITINIB; PERTUZUMAB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VATALANIB;

ALOPECIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; COLON CARCINOMA; CONFERENCE PAPER; DIMERIZATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; GENE AMPLIFICATION; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; TARGET CELL DESTRUCTION;

ALKYL AND ARYL TRANSFERASES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FARNESYLTRANSTRANSFERASE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RAS PROTEINS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; THYMIDINE PHOSPHORYLASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 5644252971     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.07.016     Document Type: Conference Paper

References (66)

1. D. Hanahan, R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
2. L.N. Klapper, M.H. Kirschbaum, M. Sela Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors Adv Cancer Res 77 2000 25 79
3. J. Mendelsohn, J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2003 2787 2799
4. Y. Yarden The EGFR family and its ligands in human cancer signalling mechanisms and therapeutic opportunities Eur J Cancer 37 2001 S3 S8
5. G. Atalay, F. Cardoso, A. Awada Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer Ann Oncol 14 2003 1346 1363
6. E. Tzahar, H. Waterman, X. Chen A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor Mol Cell Biol 16 1996 5276 5287
7. D. Graus-Porta, R.R. Beerli, J.M. Daly ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling EMBO J 16 1997 1647 1655
8. H.-S. Cho, K. Mason, K.X. Ramyar Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab Nature 421 2003 756 760
9. D. Harari, Y. Yarden Molecular mechanisms underlying ErbB2/HER2 action in breast cancer Oncogene 19 2000 6102 6114
10. Y. Yarden, M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137
11. R. Pinkas-Kramarski, L. Soussan, H. Waterman Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions EMBO J 15 1996 2452 2467
12. J. Baselga, J. Albanell Mechanism of action of anti-HER2 monoclonal antibodies Ann Oncol 12 suppl 1 2001 S35 S41
13. F.A. Shepherd, J. Pereira, T.E. Ciuleanu A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial [abstract 7022] Proc Am Soc Clin Oncol 23 2004 18
14. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
15. J.G. Paez, P.A. Janne, J.C. Lee EGFR mutations in lung cancer correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
16. W. Pao, M. Zakowski, C. Cordon-Cardo Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib [abstract 7025] Proc Am Soc Clin Oncol 23 2004 619
17. HER2 antibody for human cancer therapy Proc Natl Acad Sci U S A 89 1992 4285 4289
18. D.J. Slamon, B. Leyland-Jones, S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
19. J.M. Extra, F. Cognetti, D. Maraninchi Trastuzumab (Herceptin) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC) results of a randomised multicentre trial [abstract 239] Eur J Cancer 2 suppl 3 2004 125
20. J. Baselga, D. Tripathy, J. Mendelsohn Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 1996 737 744
21. M.A. Cobleigh, C.L. Vogel, D. Tripathy Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 1999 2639 2648
22. C.L. Vogel, M. Cobleigh, D. Tripathy Superior outcomes with Herceptin (trastuzumab) (H) in fluorescence in situ hybridization (FISH)-selected patients [abstract 86] Proc Am Soc Clin Oncol 20 2001 22a
23. J. Baselga Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer pivotal trials Oncology 61 suppl 2 2001 14 21
24. R.D. Mass, M. Press, S. Anderson Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridisation (FISH) [abstract 85] Proc Am Soc Clin Oncol 20 2001 22a
25. D.B. Agus, R.W. Akita, W.D. Fox Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Cancer Cell 2 2002 127 137
26. J. Baselga A new anti-ErbB2 strategy in the treatment of cancer prevention of ligand-dependent ErbB2 receptor heterodimerization Cancer Cell 2 2002 93 95
27. M.X. Sliwkowski Ready to partner Nat Struct Biol 10 2003 158 159
28. T.P.J. Garrett, N.M. McKern, M. Lou Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α Cell 110 2002 763 773
29. H. Ogiso, R. Ishitani, O. Nureki Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains Cell 110 2002 775 787
30. D.B. Agus, R.W. Akita, W.D. Fox A potential role for activated HER-2 in prostate cancer Semin Oncol 27 suppl 11 2000 76 83
31. D.B. Agus, M. Gordon, C. Taylor Clinical activity in a phase I trial of HER-2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies (AST) [abstract 771] Proc Am Soc Clin Oncol 22 2003 192
32. E.K. Rowinsky, J.J. Windle, D.D. Von Hoff Ras protein farnesyltransferase a strategic target for anticancer therapeutic development J Clin Oncol 17 1999 3631 3652
33. M.R. Ahmadian Prospects for anti-Ras drugs Br J Haematol 116 2002 511 518
34. J. Mazieres, A. Pradines, G. Favre Perspectives on farnesyl transferase inhibitors in cancer therapy Cancer Lett 206 2004 159 167
35. I.J. Fidler, L.M. Ellis The implications of angiogenesis for the biology and therapy of cancer metastasis Cell 79 1994 185 188
36. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1995 27 31
37. N. Ferrara, K. Carver-Moore, H. Chen Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene Nature 380 1996 439 442
38. P. Carmeliet, V. Ferreira, G. Breier Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele Nature 380 1996 435 439
39. N. Ferrara, T. Davis-Smyth The biology of vascular endothelial growth factor Endocr Rev 18 1997 4 25
40. G. Bergers, L.E. Benjamin Tumorigenesis and the angiogenic switch Nat Rev Cancer 3 2003 401 410
41. H. Gerber, V. Dixit, N. Ferrara Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells J Biol Chem 273 1998 13313 13316
42. R.K. Jain Tumor angiogenesis and accessibility role of vascular endothelial growth factor Semin Oncol 29 2002 3 9
43. R. Poon, S.T. Fan, J. Wong Clinical implications of circulating angiogenic factors in cancer patients J Clin Oncol 19 2001 1207 1225
44. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy a new paradigm for combination therapy Nat Med 7 2001 987 989
45. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
46. K. Maung Capecitabine/bevacizumab compared to capecitabine alone in pretreated metastatic breast cancer results of a phase III study Clin Breast Cancer 3 2003 375 377
47. B. Ramaswamy, C.A. Rhoades, K. Kendra CTEP-sponsored phase II trial of bevacizumab (Avastin) in combination with docetaxel (Taxotere) in metastatic breast cancer [abstract 224] Breast Cancer Res Treat 82 suppl 1 2003 S50
48. H.J. Burstein, L.M. Parker, J. Savoie Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer [abstract 446] Breast Cancer Res Treat 76 suppl 1 2002 S115
49. M. Relf, S. LeJeune, P.A. Scott Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis Cancer Res 57 1997 963 969
50. M. Los, C.J. Burek, C. Stroh Anticancer drugs of tomorrow apoptotic pathways as targets for drug design Drug Discov Today 8 2003 67 77
51. M. Kitazono, Y. Takebayashi, K. Ishitsuka Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase Biochem Biophys Res Commun 253 1998 797 803
52. Y. Takebayashi, S. Akiyama, S. Akiba Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma J Natl Cancer Inst 88 1996 1110 1117
53. M. Miwa, M. Ura, M. Nishida Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1998 1274 1281
54. H. Ishitsuka Capecitabine preclinical pharmacology studies Invest New Drugs 18 2000 343 354
55. N. Sawada, T. Ishikawa, Y. Fukase Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/taxotere in human cancer xenografts Clin Cancer Res 4 1998 1013 1019
56. N. Sawada, T. Ishikawa, F. Sekiguchi X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts Clin Cancer Res 5 1999 2948 2953
57. N. Sawada, K. Fujimoto-Ouchi, T. Ishikawa Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumour xenograft models [abstract 5388] Proc Am Assoc Cancer Res 43 2002 1088
58. K. Fujimoto-Ouchi, F. Sekiguchi, Y. Tanaka Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models Cancer Chemother Pharmacol 49 2002 211 216
59. J. Schüller, J. Cassidy, E. Dumont Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 2000 291 297
60. J. O'Shaughnessy, J. Blum, V. Moiseyenko Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer Ann Oncol 12 2001 1247 1254
61. D. Talbot, V. Moiseyenko, S. Van Belle Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines Br J Cancer 86 2002 1367 1372
62. J. Blum, S. Jones, A. Buzdar Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 17 1999 485 493
63. J. Blum, V. Dieras, P. Lo Russo Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 2001 1759 1768
64. P. Reichardt, G. Von Minckwitz, P.C. Thuss-Patience Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann Oncol 14 2003 1227 1233
65. P. Fumoleau, R. Largillier, C. Clippe Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer Eur J Cancer 40 2004 536 542
66. J. O'Shaughnessy, D. Miles, S. Vukelja Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer phase III trial results J Clin Oncol 20 2002 2812 2823